Susceptibility to antibiotic combinations among nosocomial carbapenemase-producing Gram-negative bacteria isolated in Belarus | CMAC

Susceptibility to antibiotic combinations among nosocomial carbapenemase-producing Gram-negative bacteria isolated in Belarus

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):182-191

​ Tapalskiy D.V.
10.36488//cmac.2018.3.182-191
Klebsiella pneumoniae Pseudomonas aeruginosa Acinetobacter baumannii antimicrobial resistance antibiotic combinations MCBT bactericidal activity
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):182-191

Objective.

To assess a susceptibility to antibiotic combinations in nosocomial carbapenemase-producing Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii isolates using a modified method of multiple combination bactericidal testing (MCBT).

Materials and Methods.

A total of 178 isolates (63 K. pneumoniae isolates, 31 P. aeruginosa isolates, 84 A. baumannii isolates) obtained in the 2013-2017 from hospitalized patients in 28 public health organizations in 4 Belarus regions were included in the study. All isolates were producers of the different carbapenemases (OXA-48, KPC, NDM, VIM, OXA-23, and OXA-40). The susceptibility to antimicrobial agents was determined by an automated method and a broth microdilution method. A modified MCBT method was used for determination of susceptibility to antibiotic combinations. Antibiotic concentrations corresponding to the threshold pharmacokinetic/pharmacodynamics (PK/PD) concentrations for standard doses of antimicrobial agents were used for testing antibiotic combinations. A total of 11 primary and 11 additional antibiotic combinations were tested.

Results.

The meropenem MIC values were 4 or more times higher than the threshold PK/PD concentrations for most isolates studied. A total of 42.9% of K. pneumoniae strains, 51.6% of P. aeruginosa strains and 2.4% of A. baumannii strains were non-susceptible to colistin. Using the modified MCBT method, antibiotic combinations with bactericidal activity were detected for 177 (99.4%) isolates; 3 or more antibiotic combinations were bactericidal for 155 isolates (87.1%). The colistin-containing combinations were the most active, including against isolates with colistin MIC values above the threshold PK/PD concentration. The bactericidal activity of meropenem + amikacin and amikacin + levofloxacin combinations against 51.9% of K. pneumoniae colistin-resistant isolates was determined. The meropenem + colistin (85.7%) and imipenem + colistin (84.1%) combinations were the most active against P. aeruginosa. All the colistincontaining combinations were bactericidal against nearly 100% of A. baumannii isolates.

Conclusions.

Species-level and strain-level specificity of bactericidal activity for the different antibiotic combinations was found.

Dmitry V. Tapalskiy

Gomel State Medical University, Gomel, Belarus

  • 1. Karaiskos I., Giamarellou H. Multidrug-resistant and extensively drugresistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351-1370.
  • 2. Tangden T., Giske C.G. Global dissemination of extensively drugresistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501-512.
  • 3. Zavascki A.P., Bulitta J.B., Landersdorfer C.B. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11:1333-1353.
  • 4. Cai Y., Chua N.G., Lim T.P., et al. From bench-top to bedside: a prospective in vitro antibiotic combination testing (iACT) service to guide the selection of rationally optimized antimicrobial combinations against extensively drug resistant (XDR) Gram negative bacteria (GNB). PLoS One. 2016;11(7):e0158740.
  • 5. Perez F., El Chakhtoura N.G., Papp-Wallace K.M., Wilson B.M., Bonomo R.A. Treatment options for infections caused by carbapenemresistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17:761-781.
  • 6. Laishram S., Pragasam A.K., Bakthavatchalam Y.D., Veeraraghavan B. An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J Med Microbiol. 2017;35(4):445-468.
  • 7. Doern C.D. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52(12):4124-4128.
  • 8. NCCLS, Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
  • 9. White R.L., Burgess D.S., Manduru M., Bosso J.A. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E-test. Antimicrob Agents Chemother. 1996;40:1914-1918.
  • 10. Manno G., Ugolotti E., Belli M.L., et al. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2003;22:28-34.
  • 11. Sopirala M.M., Mangino J.E., Gebreyes W.A., et al. Synergy testing by etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:4678-4683.
  • 12. Tapalski D.V. Bacteriophage preparations and combinations of antibiotics: in vitro activity in regard to extensively drug-resistant isolates of Pseudomonas aeruginosa ST235. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(4):242-248. Russian.
  • 13. Tripodi M.F., Durante-Mangoni E., Fortunato R., Utili R., Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents. 2007;30:537540.
  • 14. Aaron S.D., Ferris W., Henry D.A., Speert D.P., Macdonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Resp Crit Care Med. 2000;161(4):1206-1212.
  • 15. Lang B.J., Aaron S.D., Ferris W., Hebert P.C., MacDonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2000;162(6):2241-2245.
  • 16. Foweraker J.E., Laughton C.R., Brown D.F., Bilton D. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother. 2009;53(11):4809-4815.
  • 17. Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr Respir Rev. 2007;8(3):249-255.
  • 18. Waters V., Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2017;6:CD006961.
  • 19. Mezzatesta M.L., Caio C., Gona F., et al. Colistin increases the cidal activity of antibiotic combinations against multidrug-resistant Klebsiella pneumoniae: an in vitro model comparing multiple combination bactericidal testing at one peak serum concentration and time-kill method. Microb Drug Resist. 2016;22(5):360-363.
  • 20. Teo J., Lim T.P., Hsu L.Y., et al. Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal polymyxin B-based combinations. Antimicrob Resist Infect Control. 2015;4(1):2.
  • 21. Aaron S.D., Vandemheen K.L., Ferris W., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, doubleblind, controlled clinical trial. Lancet. 2005;366(9484):463-471.
  • 22. Flume P.A., Mogayzel P.J., Robinson K.A., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Resp Crit Care Med. 2009;180:802-808.
  • 23. Mydin H.H., Corris P.A., Nicholson A., et al. Targeted antibiotic prophylaxis for lung transplantation in cystic fibrosis patients colonised with Pseudomonas aeruginosa using multiple combination bactericidal testing. J Transplant. 2012;2012:135738.
  • 24. Tapalski D.V., Lagun L.V. Methods for determining sensitivity to combinations of antibiotics of Gram-negative bacteria with extensively drug resistance and pandrug resistance. Instructions for use. Ministry of Health of the Republic of Belarus, 2017. Registration number 0020517. Russian.
  • 25. Tapalski D.V., Osipov V.A., Yevseyenko E.O., et al. Metallo-betalactamases and carbapenemases among extensively antibioticresistant enterobacteria: occurrence in Belarus. Zdravoohranenie. 2017;3:40-47. Russian.
  • 26. Tapalski D.V., Osipov V.A., Zhavoronok S.V. Carbapenemases of gram-negative pathogens: spread and methods of detection. Meditsinskii zhurnal. 2012;2(40);10-15. Russian.
  • 27. Tapalski D.V., Bonda N.A., Lagun L.V. Microbiological monitoring system of extensively drug-resistant and pandrug-resistant bacterial pathogens determining the sensitivity to antibiotic combinations. Vestnik of Vitebsk State Medical University. 2018;17(1):50-58. Russian.
  • 28. Vasoo S. Susceptibility testing for the polymyxins: two steps back, three steps forward? J Clin Microbiol. 2017;55(9):2573-2582.
  • 29. Chew K.L., La M.V., Lin R.T.P., Teo J.W.P. Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with broth microdilution. J Clin Microbiol. 2017;55(9):26092616.
  • 30. ISO 20776-1:2006 «Clinical laboratory testing and in vitro diagnostic test systems – Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices» – Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.
  • 31. European Committee on Antimicrobial Susceptibility testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Ver. 8.0 2018. Available at: www.eucast.org/clinical_breakpoints/.
  • 32. CLSI, Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared